Vaccinare
Vaccinazione contro la parotite epidemica
1BARBARA MASPES E 2ROBERTO MENTA 1Servizio di Farmacovigilanza e 1BARBARA MASPES E 2ROBERTO MENTA
1Servizio di Farmacovigilanza e 2Divisione Scientifica e Marketing dell’Istituto Sieroterapico Berna (Como)Divisione Scientifica e Marketing dell’Istituto Sieroterapico Berna (Como)
Ottobre 1998 - pagg. 547 -548
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
SC: The interruption of transmission of indigenous
measles in the United States during
1993. Pediatr Infect Dis J 17, 363-6, 1998.
2. Istituto Nazionale di Statistica: Statistiche della Sanità, anno 1993. Annuario n. 9, 207, 1996.
3. CDC Atlanta: Progress toward elimination of measles from the Americas. MMWR 47 (10), 189-193, 1998.
4. CDC Atlanta: Recommended childhood immunization schedule - United States, 1998. MMWR 47 (1), 8-12, 1998.
5. Forsey T, Health AB, Minor PD: A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines. Biologicals 21, 239-249, 1993.
6. Minor PD: Laboratory tests of mumps vaccines. Biologicals 25, 35-40, 1997.
7. Gray JA, Burns SM: Mumps meningitis following measles, mumps and rubella immunization. Lancet 98, 1989.
8. Von Muhlendahl KE, et al: Mumps meningitis following measles, mumps and rubella immunization. Lancet 394-395, 1989.
9. Nalin DR: Mumps vaccine complications: which strain? Lancet 1396, 1989.
10. Ehrengut W. Mumps vaccine and meningitis. Lancet 751, 1989.
11. Mumps meningitis and MMR vaccination. Lancet 1015-1016, 1989.
12. Mumps meningitis possibly vaccine related - Ontario. Canada Diseases Weekly Report 14-46, 209-211, 1988.
13. Sugiura A, Yamada A: Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 10, 209-213, 1991.
14. Brown EG, Fusesz J, Dimock K, Yarosh W, Contreras G: Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. Vaccine 9, 840-842, 1991.
15. Fujinaga T, Motegi Y, Tamura H, Kuroume T: A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine. Pediatr Infect Dis J 10, 204-209, 1991.
16. Tabin PR, Berclaz JP, Dupuis G, Peter O: Réponse immune à divers vaccins anti-ourliens. Revue Médicale de la Suisse Romande 113, 981-984, 1993.
17. Euro-Surveillance - European Communicable Disease Bulletin: Mumps epidemic in Portugal despite high vaccine coverage - Preliminary report. 1 (no.4), 1996.
18. Boletin Epidemiologico Semanal - Red Nacional de vigilancia epidemiolgica de Espana centro national de epidemiologia. Situacion de la parotitis en Espana durante
1996. 5 (no.2), 13, 1997.
19. Briss PA, Fehrs LJ, Parker RA, et al: Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine - induced immunity. J Infect Dis 169, 77-82, 1994.
20. CDC Atlanta. Summary of notifiable diseases, United States 1993. MMWR 42 (53), 3, 1993.
21. Peltola H, Heinonen OP, Valle M, et al: The elimination of indigenous measles, mumps and rubella from Finland by a 12- year, two-dose vaccination program. N Engl J Med 331 (21), 1397-1402, 1994.
22. Gay N, Miller E, Hesketh L, et al: Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Communicable Disease Report 7 (2), 1997.
23. Schwarzer S, Reibel S, Lang AB, et al: Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccine. Vaccine 16 (2/3), 298-304, 1998.
1993. Pediatr Infect Dis J 17, 363-6, 1998.
2. Istituto Nazionale di Statistica: Statistiche della Sanità, anno 1993. Annuario n. 9, 207, 1996.
3. CDC Atlanta: Progress toward elimination of measles from the Americas. MMWR 47 (10), 189-193, 1998.
4. CDC Atlanta: Recommended childhood immunization schedule - United States, 1998. MMWR 47 (1), 8-12, 1998.
5. Forsey T, Health AB, Minor PD: A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines. Biologicals 21, 239-249, 1993.
6. Minor PD: Laboratory tests of mumps vaccines. Biologicals 25, 35-40, 1997.
7. Gray JA, Burns SM: Mumps meningitis following measles, mumps and rubella immunization. Lancet 98, 1989.
8. Von Muhlendahl KE, et al: Mumps meningitis following measles, mumps and rubella immunization. Lancet 394-395, 1989.
9. Nalin DR: Mumps vaccine complications: which strain? Lancet 1396, 1989.
10. Ehrengut W. Mumps vaccine and meningitis. Lancet 751, 1989.
11. Mumps meningitis and MMR vaccination. Lancet 1015-1016, 1989.
12. Mumps meningitis possibly vaccine related - Ontario. Canada Diseases Weekly Report 14-46, 209-211, 1988.
13. Sugiura A, Yamada A: Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 10, 209-213, 1991.
14. Brown EG, Fusesz J, Dimock K, Yarosh W, Contreras G: Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. Vaccine 9, 840-842, 1991.
15. Fujinaga T, Motegi Y, Tamura H, Kuroume T: A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine. Pediatr Infect Dis J 10, 204-209, 1991.
16. Tabin PR, Berclaz JP, Dupuis G, Peter O: Réponse immune à divers vaccins anti-ourliens. Revue Médicale de la Suisse Romande 113, 981-984, 1993.
17. Euro-Surveillance - European Communicable Disease Bulletin: Mumps epidemic in Portugal despite high vaccine coverage - Preliminary report. 1 (no.4), 1996.
18. Boletin Epidemiologico Semanal - Red Nacional de vigilancia epidemiolgica de Espana centro national de epidemiologia. Situacion de la parotitis en Espana durante
1996. 5 (no.2), 13, 1997.
19. Briss PA, Fehrs LJ, Parker RA, et al: Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine - induced immunity. J Infect Dis 169, 77-82, 1994.
20. CDC Atlanta. Summary of notifiable diseases, United States 1993. MMWR 42 (53), 3, 1993.
21. Peltola H, Heinonen OP, Valle M, et al: The elimination of indigenous measles, mumps and rubella from Finland by a 12- year, two-dose vaccination program. N Engl J Med 331 (21), 1397-1402, 1994.
22. Gay N, Miller E, Hesketh L, et al: Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Communicable Disease Report 7 (2), 1997.
23. Schwarzer S, Reibel S, Lang AB, et al: Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccine. Vaccine 16 (2/3), 298-304, 1998.